Please login to the form below

Not currently logged in

Merck ends HIV drug study

Merck is to end its study investigating once-daily Isentress for patients with HIV-1 after it failed to improve on a twice-daily version

Merck is to end its study investigating once-daily Isentress (raltegravir) for patients with HIV-1 after the drug failed to improve on an already approved twice-daily version in a phase III trial.

The trial evaluated the safety and efficacy of an investigational once-daily 800mg dose of the drug against the approved twice-daily 400mg dose, each in combination with a once-daily dose of emtricitabine and tenofovir disoproxil fumarate, in adult treatment-naïve HIV-1-infected patients.

Of the patients taking the once-daily does, 83.2 per cent achieved undetectable viral levels, compared to 88.9 per cent of patients in the twice-daily group. This difference, however, did not meet the pre-defined statistical criteria for non-inferiority.

Drug safety was found to be similar in both regimens, and consistent with current labelling for Isentress.

The 400mg version of the drug is currently the only approved integrase inhibitor for the treatment of HIV-1. It works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme.

Merck said it is notifying clinical investigators of the decision to cancel the trial this week, with a recommendation that patients enrolled in the once-daily dosing arm of the study be switched to Isentress twice daily.

30th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...